Stockscreener 앱 받기
0.4961
5.86%
-0.0309
Calidi Biotherapeutics Inc 주식(CLDI)의 최신 뉴스
ASP Isotopes and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - ACCESS Newswire
HighTower Advisors LLC Makes New Investment in Calidi Biotherapeutics, Inc. (NYSE:CLDI) - Defense World
Calidi Biotherapeutics Announces Closing of $3.9 Million Registered Direct Offering and Concurrent Private Placement - GlobeNewswire
CLDI stock plunges to 52-week low, hitting $0.57 amid market challenges By Investing.com - Investing.com South Africa
Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Operational Highlights - The Manila Times
Calidi Bio Raises Fresh $3.9M Capital to Advance Clinical Programs - Stock Titan
Calidi Biotherapeutics Cuts Losses by 50% While Expanding Cancer Gene Therapy Trials - Stock Titan
CLDI stock plunges to 52-week low, hitting $0.57 amid market challenges - Investing.com India
Virtu Financial LLC Buys Shares of 73,448 Calidi Biotherapeutics, Inc. (NYSE:CLDI) - Defense World
Calidi Biotherapeutics sinks after pricing $3.9M registered direct offering - MSN
Calidi prices 3.33M shares at 65c in registered direct offering - TipRanks
Calidi Biotherapeutics Announces Pricing of $3.9 Million Registered Direct Offering and Concurrent Private Placement - GlobeNewswire
Calidi Bio Secures Strategic $3.9M Investment to Accelerate Cancer Immunotherapy Pipeline - Stock Titan
Calidi Biotherapeutics Provides Update On Phase 1 Trial Of CLD-101 For Recurrent Glioma - Nasdaq
Calidi Biotherapeutics and City of Hope Provide Update on a - GlobeNewswire
Calidi Biotherapeutics And City Of Hope Provide Update On A Phase 1 Clinical Trial With CLD-101 Virotherapy In Patients With Recurrent High-Grade Glioma - MarketScreener
Breakthrough Brain Cancer Treatment Advances: 14 Patients Successfully Treated in Groundbreaking Trial - Stock Titan
CLDI stock touches 52-week low at $0.73 amid market challenges - MSN
Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Weatherford Democrat
IBN Coverage: Calidi Biotherapeutics (NYSE American: CLDI) Reports Promising Preclinical Results for RTNova Virotherapy Platform - Yahoo Finance
Calidi’s Rtnova platform delivers transient gene therapy payloads to tumors - BioWorld Online
Calidi Biotherapeutics (NYSE American: CLDI) Reports Promising Preclinical Results for RTNova Virotherapy Platform - Benzinga
Calidi Biotherapeutics Announces Promising Preclinical Results - TipRanks
Calidi announces ability to deliver transient gene therapy to tumors - TipRanks
Calidi Biotherapeutics Announces Demonstrated Ability To - GlobeNewswire
Calidi Reports Breakthrough: Cancer Platform Kills 60+ Tumor Types - StockTitan
Critical Review: Eloxx Pharmaceuticals (NASDAQ:ELOX) versus Calidi Biotherapeutics (NYSE:CLDI) - Defense World
Calidi Biotherapeutics prices $7.5M secondary offering - MSN
Calidi Biotherapeutics and OS Therapies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - WSIL TV
Calidi Biotherapeutics is initiating GMP manufacturing at VetStem BioPharma, a veterinary and human regenerative medicine company in San Diego, CA - ACCESS Newswire
Inside Calidi Biotherapeutics: CFO Andrew Jackson Breaks Down the Future of Oncolytic Virotherapy - Audacy
Calidi Biotherapeutics Inc. (NYSE American: CLDI) Drives Growth With Strengthened Financial Position And Cutting-Edge Research - MENAFN.COM
Calidi Biotherapeutics Announces Commencement of - GlobeNewswire
Closing Figures Unveiled: Calidi Biotherapeutics Inc (CLDI) Drop -16.67, Closes at 1.05 - The Dwinnex
Calidi Biotherapeutics Announces Commencement of Recruitment for Multiple Dose CLD-101 Trial in Patients with Newly Diagnosed High Grade Glioma at Northwestern University Hospital - The Manila Times
Calidi Biotherapeutics Initiates Recruitment for CLD-101 Clinical Trial Targeting High-Grade Glioma - Nasdaq
Can Multiple Doses Make This Brain Cancer Treatment More Effective? Northwestern Launches Next-Phase Trial - StockTitan
Calidi Biotherapeutics Inc (CLDI) rating initates by H.C. Wainwright - Knox Daily
Taking on analysts’ expectations and winning: Calidi Biotherapeutics Inc (CLDI) - SETE News
CLDI’s 2023 Market Dance: Up 13.04% – Time to Invest? - The InvestChronicle
A review of CLDI’s current quarter earnings predictions - US Post News
What Recent Market Trends Mean for Calidi Biotherapeutics Inc’s (CLDI) Stock - The News Heater
Calidi Biotherapeutics expands stock offering capacity - Investing.com India
Calidi Biotherapeutics expands stock offering capacity By Investing.com - Investing.com South Africa
Market Recap: Calidi Biotherapeutics Inc (CLDI)’s Positive Momentum, Closing at 1.32 - The Dwinnex
For Calidi Biotherapeutics Inc [CLDI], Analyst sees a rise to $11. What next? - The DBT News
Calidi Biotherapeutics Inc Inc. (CLDI) Price Performance: A Fundamental Analysis Perspective - The InvestChronicle
Get in on Calidi Biotherapeutics Inc’s (CLDI) buy-in window today! - SETE News
Taking a Closer Look At Calidi Biotherapeutics Inc (CLDI) Following Its Recent Trade - Knox Daily
CLDI’s price-to-sales ratio: A comparative analysis with its peers - US Post News
CLDI Stock Plummets to 52-Week Low at $0.6 Amid Market Turbulence - Investing.com Australia
3.01%
자본화:
|
볼륨(24시간):